乳腺癌和真实世界研究_West China Medical Journal

Authors：

 胡前程 ^1,2 , 吴娜娜 ¹ , 罗婷 ² , 郑鸿 ² ,  李昌林 ¹

1. ;
2. ;

Corresponding author：

胡前程, Email: hqch860109@163.com; 李昌林, Email: 1965841265@qq.com

Keywords：

乳腺癌; 真实世界研究; 信息登记系统

DOI：

10.7507/1002-0179.201600157

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

真实世界研究一般采用大样本人群，根据患者的实际病情和意愿，非随机选择治疗措施，开展长期评价，注重有意义的结局治疗，评价临床实践的外部有效性和安全性。真实世界研究起源于实用性研究，成为了医疗管理者、医务工作人员及患者之间的信息传递纽带。真实世界研究涵盖的范围较广，除治疗性研究外，还可用于病因、诊断、预后等方面的研究，评价新药或检测方法的采用率、安全性、不良反应及患者生存情况。真实世界研究在心血管领域流行甚早，在肿瘤学方面则刚刚起步，乳腺癌信息登记系统的迅速发展为真实世界研究提供了一个崭新的平台。真实世界研究同样可以应用于乳腺癌诊断方面、治疗和预后方面。乳腺癌的真实世界研究正越来越具有科学性和实践性。

Citation： 胡前程, 吴娜娜, 罗婷, 郑鸿, 李昌林. 乳腺癌和真实世界研究. West China Medical Journal, 2016, 31(3): 589-591. doi: 10.7507/1002-0179.201600157 Copy

1.	Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS):a tool to help trial designers[J]. J Clin Epidemiol, 2009, 62(5) :464-475.
2.	Freemantle N, Strack T. Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials[J]. J Clin Epidemiol, 2010, 63(10) :1053-1058.
3.	Krumholz HM. Real-world imperative of outcomes research[J]. JAMA, 2011, 306(7) :754-755.
4.	Booth CM, Mackillop WJ. Translating new medical therapies into societal benefit:the role of population-based outcome studies[J]. JAMA, 2008, 300(18) :2177-2179.
5.	Al-Refaie WB, Vickers SM, Zhong W, et al. Cancer trials versus the real world in the United States[J]. Ann Surg, 2011, 254(3) :438-442; discussion 442-443.
6.	Hu Q, Luo T, He P, et al. Trends and present treatment patterns of early breast cancer in Southwest China[J]. Pathol Oncol Res, 2015, 21(2) :367-378.
7.	Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE)[J]. Eur Heart J, 2002, 23(15) :1177-1189.
8.	Booth CM, Shepherd FA, Peng Y, et al. Adoption of adjuvant chemotherapy for non-small-cell lung cancer:a population-based outcomes study[J]. J Clin Oncol, 2010, 28(21) :3472-3478.
9.	胡前程, 郑鸿. 由乳腺癌看真实世界研究(RWR)[EB/OL]. (2013-08-19) [2014-11-01]. http://www.medelites.com/1402.html.
10.	Parkin DM. The evolution of the population-based cancer registry[J]. Nat Rev Cancer, 2006, 6(8) :603-612.
11.	Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer:the California Cancer Registry, 1999-2004[J]. Cancer, 2008, 112(4) :737-747.
12.	Parise CA, Caggiano V. Disparities in race/ethnicity and socioeconomic status:risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010[J]. BMC Cancer, 2013, 13:449.
13.	Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience[J]. J Natl Cancer Inst, 2002, 94(11) :852-854.
14.	Tarantini L, Cioffi G, Gori S, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer[J]. J Card Fail, 2012, 18(2) :113-119.
15.	Vichapat V, Garmo H, Holmqvist M, et al. Tumor stage affects risk and prognosis of contralateral breast cancer:results from a large Swedish-population-based study[J]. J Clin Oncol, 2012, 30(28) :3478-3485.
16.	Madarnas Y, Dent SF, Husain SF, et al. Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres[J]. Curr Oncol, 2011, 18(3) :119-125.
17.	Hu Q, Luo T, Zhong X, et al. Application status of tamoxifen in endocrine therapy for early breast cancer[J]. Exp Ther Med, 2015, 9(6) :2207-2212.

1. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS):a tool to help trial designers[J]. J Clin Epidemiol, 2009, 62(5) :464-475.
2. Freemantle N, Strack T. Real-world effectiveness of new medicines should be evaluated by appropriately designed clinical trials[J]. J Clin Epidemiol, 2010, 63(10) :1053-1058.
3. Krumholz HM. Real-world imperative of outcomes research[J]. JAMA, 2011, 306(7) :754-755.
4. Booth CM, Mackillop WJ. Translating new medical therapies into societal benefit:the role of population-based outcome studies[J]. JAMA, 2008, 300(18) :2177-2179.
5. Al-Refaie WB, Vickers SM, Zhong W, et al. Cancer trials versus the real world in the United States[J]. Ann Surg, 2011, 254(3) :438-442; discussion 442-443.
6. Hu Q, Luo T, He P, et al. Trends and present treatment patterns of early breast cancer in Southwest China[J]. Pathol Oncol Res, 2015, 21(2) :367-378.
7. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE)[J]. Eur Heart J, 2002, 23(15) :1177-1189.
8. Booth CM, Shepherd FA, Peng Y, et al. Adoption of adjuvant chemotherapy for non-small-cell lung cancer:a population-based outcomes study[J]. J Clin Oncol, 2010, 28(21) :3472-3478.
9. 胡前程, 郑鸿. 由乳腺癌看真实世界研究(RWR)[EB/OL]. (2013-08-19) [2014-11-01]. http://www.medelites.com/1402.html.
10. Parkin DM. The evolution of the population-based cancer registry[J]. Nat Rev Cancer, 2006, 6(8) :603-612.
11. Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer:the California Cancer Registry, 1999-2004[J]. Cancer, 2008, 112(4) :737-747.
12. Parise CA, Caggiano V. Disparities in race/ethnicity and socioeconomic status:risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010[J]. BMC Cancer, 2013, 13:449.
13. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience[J]. J Natl Cancer Inst, 2002, 94(11) :852-854.
14. Tarantini L, Cioffi G, Gori S, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer[J]. J Card Fail, 2012, 18(2) :113-119.
15. Vichapat V, Garmo H, Holmqvist M, et al. Tumor stage affects risk and prognosis of contralateral breast cancer:results from a large Swedish-population-based study[J]. J Clin Oncol, 2012, 30(28) :3478-3485.
16. Madarnas Y, Dent SF, Husain SF, et al. Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres[J]. Curr Oncol, 2011, 18(3) :119-125.
17. Hu Q, Luo T, Zhong X, et al. Application status of tamoxifen in endocrine therapy for early breast cancer[J]. Exp Ther Med, 2015, 9(6) :2207-2212.

Previous Article
不适宜的左心室质量
Next Article
原发性中枢神经系统淋巴瘤一例诊疗分析

West China Medical Journal

乳腺癌和真实世界研究

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content